Alexx Weaver

Researcher

University of Arkansas for Medical Sciences

faculty

2 h-index 10 pubs 14 cited

Is this your profile? Verify and claim your profile

Biography and Research Information

OverviewAI-generated summary

Alexx Weaver's research investigates the anticancer mechanisms of natural compounds and their synergistic effects with chemotherapy. Publications focus on the role of prenylated stilbenoids, such as Arachidin-1, in enhancing the efficacy of paclitaxel against triple-negative and hormone receptor-positive breast cancer cells. Weaver also studies the anti-leishmanial properties of disquaramide compounds. Additionally, recent work explores the link between enhanced translational activity and lymphatic endothelial cell activation in cutaneous leishmaniasis. Weaver collaborates with researchers at the University of Arkansas for Medical Sciences and Arkansas State University. With a total of 10 publications and 14 citations, Weaver's h-index is 2, and their work is recently active.

Metrics

  • h-index: 2
  • Publications: 10
  • Citations: 14

Selected Publications

  • Enhanced translational activity is linked to lymphatic endothelial cell activation in cutaneous leishmaniasis 4267 (2025) DOI
  • Enhanced Translational Activity Is Linked to Lymphatic Endothelial Cell Activation in Cutaneous Leishmaniasis (2025) DOI
  • Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs (2024) DOI
  • Enhanced translational activity is linked to lymphatic endothelial cell activation in cutaneous leishmaniasis (2024) DOI
  • Stilbene-rich extract increases the cytotoxic effects of paclitaxel in hormone receptor-positive and triple-negative breast cancer spheroids (2024) DOI
  • Arachidin-1, a Prenylated Stilbenoid from Peanut, Enhances the Anticancer Effects of Paclitaxel in Triple-Negative Breast Cancer Cells (2023) DOI
  • Elucidating the Anticancer Mechanism of Arachidin‐1 in Triple‐Negative Breast Cancer Cells (2022) DOI
  • Prenylated Stilbenoids as Potential Adjuvants for Paclitaxel in the Treatment of Triple‐Negative Breast Cancer (2022) DOI

Collaborators

Researchers in the database who share publications

Similar Researchers

Based on overlapping research topics